LIPID MANAGEMENT

R. Scott Wright; Joseph G. Murphy

doi:10.1201/b14283-102

LIPID MANAGEMENT

R. Scott Wright, Joseph G. Murphy

Cardiovascular Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA ▪ Goal-directed therapy for dyslipidemia is outlined in Table 1. Statins ▪ Statin agents work through at least two mechanisms in patients with dyslipidemia. ▪ Statins inhibit the enzyme responsible for the rate limit-ing step of cholesterol biosynthesis and HMG coenzyme A reductase and thus directly inhibit cholesterol biosynthesis.

Original language	English (US)
Title of host publication	Mayo Clinic Medical Manual
Publisher	CRC Press
Pages	821-824
Number of pages	4
ISBN (Electronic)	9781420003833
ISBN (Print)	9780849390876
DOIs	https://doi.org/10.1201/b14283-102
State	Published - Jan 1 2006

ASJC Scopus subject areas

General Medicine

Access to Document

10.1201/b14283-102

Cite this

@inbook{d7018c0edf93411bb37e2f116297c0ee,

title = "LIPID MANAGEMENT",

abstract = "PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA ▪ Goal-directed therapy for dyslipidemia is outlined in Table 1. Statins ▪ Statin agents work through at least two mechanisms in patients with dyslipidemia. ▪ Statins inhibit the enzyme responsible for the rate limit-ing step of cholesterol biosynthesis and HMG coenzyme A reductase and thus directly inhibit cholesterol biosynthesis.",

author = "Wright, {R. Scott} and Murphy, {Joseph G.}",

note = "Publisher Copyright: {\textcopyright} 2006 by Taylor & Francis Group, LLC.",

year = "2006",

month = jan,

day = "1",

doi = "10.1201/b14283-102",

language = "English (US)",

isbn = "9780849390876",

pages = "821--824",

booktitle = "Mayo Clinic Medical Manual",

publisher = "CRC Press",

}

TY - CHAP

T1 - LIPID MANAGEMENT

AU - Wright, R. Scott

AU - Murphy, Joseph G.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA ▪ Goal-directed therapy for dyslipidemia is outlined in Table 1. Statins ▪ Statin agents work through at least two mechanisms in patients with dyslipidemia. ▪ Statins inhibit the enzyme responsible for the rate limit-ing step of cholesterol biosynthesis and HMG coenzyme A reductase and thus directly inhibit cholesterol biosynthesis.

AB - PHARMACOLOGIC TREATMENT OF DYSLIPIDEMIA ▪ Goal-directed therapy for dyslipidemia is outlined in Table 1. Statins ▪ Statin agents work through at least two mechanisms in patients with dyslipidemia. ▪ Statins inhibit the enzyme responsible for the rate limit-ing step of cholesterol biosynthesis and HMG coenzyme A reductase and thus directly inhibit cholesterol biosynthesis.

UR - http://www.scopus.com/inward/record.url?scp=85178609693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178609693&partnerID=8YFLogxK

U2 - 10.1201/b14283-102

DO - 10.1201/b14283-102

M3 - Chapter

AN - SCOPUS:85178609693

SN - 9780849390876

SP - 821

EP - 824

BT - Mayo Clinic Medical Manual

PB - CRC Press

ER -

LIPID MANAGEMENT

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this